About
Novocure is a global oncology company pioneering innovative therapies for cancer treatment. Founded in 2000 in Saint Helier, Jersey, the company focuses on the development and commercialization of Tumor Treating Fields (TTFields), a groundbreaking therapy that uses electric fields to disrupt cancer cell division and inhibit tumor growth. Novocure has rapidly gained recognition for its commitment to improving the lives of cancer patients.
TTFields, Novocure’s flagship technology, represents a non-invasive treatment option that targets various forms of cancer, including glioblastoma and mesothelioma. This therapy works by delivering alternating electric fields to the tumor site, which interfere with the mitotic process of cancer cells, thereby slowing down or stopping their proliferation. The unique mechanism of TTFields offers a complementary approach to traditional treatments like chemotherapy and radiation, providing patients with additional options in their fight against cancer.
Novocure’s dedication to advancing cancer treatment is reflected in its robust clinical research programs and collaborations with leading medical institutions worldwide. The company continuously invests in expanding the applications of TTFields, with ongoing studies exploring its efficacy in treating other types of solid tumors. By pushing the boundaries of cancer therapy, Novocure aims to make a significant impact on global health and bring hope to patients battling this devastating disease.
